On 9 November 2012 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.
Further informationMedia: | ||
Anne Margrethe Hauge | +45 4442 3450 | amhg@novonordisk.com |
Ken Inchausti (US) | +1 609 514 8316 | kiau@novonordisk.com |
Investors: | ||
Kasper Roseeuw Poulsen | +45 4442 4303 | krop@novonordisk.com |
Frank Daniel Mersebach | +45 4442 0604 | fdni@novonordisk.com |
Lars Borup Jacobsen | +45 3075 3479 | lbpj@novonordisk.com |
Jannick Lindegaard (US) | +1 609 786 4575 | jlis@novonordisk.com |
Company announcement No 01 / 2013
Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.
Headquartered in Denmark, Novo Nordisk employs approximately 33,900 employees in 75 countries, and markets its products in 190 countries.
distributed by
|